Pathophysiology, treatment, and animal and cellular models of human ischemic stroke

被引:426
作者
Woodruff, Trent M. [1 ]
Thundyil, John [1 ]
Tang, Sung-Chun [2 ,3 ,4 ]
Sobey, Christopher G. [5 ]
Taylor, Stephen M. [1 ]
Arumugam, Thiruma V. [1 ]
机构
[1] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia
[2] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan
[4] Natl Taiwan Univ Coll Med, Taipei, Taiwan
[5] Monash Univ, Dept Pharmacol, Clayton, Vic 3800, Australia
来源
MOLECULAR NEURODEGENERATION | 2011年 / 6卷
关键词
CEREBRAL-ARTERY OCCLUSION; HIPPOCAMPAL SLICE CULTURES; OXYGEN-GLUCOSE DEPRIVATION; TISSUE-PLASMINOGEN ACTIVATOR; TOLL-LIKE RECEPTORS; IONOTROPIC GLUTAMATE-RECEPTOR; ADHESION MOLECULE-1 ANTIBODY; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE;
D O I
10.1186/1750-1326-6-11
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Stroke is the world's second leading cause of mortality, with a high incidence of severe morbidity in surviving victims. There are currently relatively few treatment options available to minimize tissue death following a stroke. As such, there is a pressing need to explore, at a molecular, cellular, tissue, and whole body level, the mechanisms leading to damage and death of CNS tissue following an ischemic brain event. This review explores the etiology and pathogenesis of ischemic stroke, and provides a general model of such. The pathophysiology of cerebral ischemic injury is explained, and experimental animal models of global and focal ischemic stroke, and in vitro cellular stroke models, are described in detail along with experimental strategies to analyze the injuries. In particular, the technical aspects of these stroke models are assessed and critically evaluated, along with detailed descriptions of the current best-practice murine models of ischemic stroke. Finally, we review preclinical studies using different strategies in experimental models, followed by an evaluation of results of recent, and failed attempts of neuroprotection in human clinical trials. We also explore new and emerging approaches for the prevention and treatment of stroke. In this regard, we note that single-target drug therapies for stroke therapy, have thus far universally failed in clinical trials. The need to investigate new targets for stroke treatments, which have pleiotropic therapeutic effects in the brain, is explored as an alternate strategy, and some such possible targets are elaborated. Developing therapeutic treatments for ischemic stroke is an intrinsically difficult endeavour. The heterogeneity of the causes, the anatomical complexity of the brain, and the practicalities of the victim receiving both timely and effective treatment, conspire against developing effective drug therapies. This should in no way be a disincentive to research, but instead, a clarion call to intensify efforts to ameliorate suffering and death from this common health catastrophe. This review aims to summarize both the present experimental and clinical state-of-the art, and to guide future research directions.
引用
收藏
页数:19
相关论文
共 174 条
[1]   Cellular oxygen sensing need in CNS function: physiological and pathological implications [J].
Acker, T ;
Acker, H .
JOURNAL OF EXPERIMENTAL BIOLOGY, 2004, 207 (18) :3171-3188
[2]   Oxidative stress and its role in the pathogenesis of ischaemic stroke [J].
Allen, C. L. ;
Bayraktutan, U. .
INTERNATIONAL JOURNAL OF STROKE, 2009, 4 (06) :461-470
[3]   Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator [J].
Alvarez-Sabin, Jose ;
Huertas, Rafael ;
Quintana, Manolo ;
Rubiera, Marta ;
Delgado, Pilar ;
Ribo, Marc ;
Molina, Carlos A. ;
Montaner, Joan .
STROKE, 2007, 38 (03) :1076-1078
[4]  
[Anonymous], Who global infobase
[5]  
[Anonymous], Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
[6]   NEUROPROTECTION IN STROKE BY COMPLEMENT INHIBITION AND IMMUNOGLOBULIN THERAPY [J].
Arumugam, T. V. ;
Woodruff, T. M. ;
Lathia, J. D. ;
Selvaraj, P. K. ;
Mattson, M. P. ;
Taylor, S. M. .
NEUROSCIENCE, 2009, 158 (03) :1074-1089
[7]   Targeting ischemic brain injury with intravenous immunoglobulin [J].
Arumugam, Thiruma V. ;
Selvaraj, Pradeep K. ;
Woodruff, Trent M. ;
Mattson, Mark P. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2008, 12 (01) :19-29
[8]   Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death [J].
Arumugam, Thiruma V. ;
Tang, Sung-Chun ;
Lathia, Justin D. ;
Cheng, Aiwu ;
Mughal, Mohamed R. ;
Chigurupati, Srinivasulu ;
Magnus, Tim ;
Chan, Sic L. ;
Jo, Dong-Gyu ;
Ouyang, Xin ;
Fairlie, David P. ;
Granger, Daniel N. ;
Vortmeyer, Alexander ;
Basta, Milan ;
Mattson, Mark P. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (35) :14104-14109
[9]   Age and Energy Intake Interact to Modify Cell Stress Pathways and Stroke Outcome [J].
Arumugam, Thiruma V. ;
Phillips, Terry M. ;
Cheng, Aiwu ;
Morrell, Christopher H. ;
Mattson, Mark P. ;
Wan, Ruiqian .
ANNALS OF NEUROLOGY, 2010, 67 (01) :41-52
[10]   TOLL-LIKE RECEPTORS IN ISCHEMIA-REPERFUSION INJURY [J].
Arumugam, Thiruma V. ;
Okun, Eitan ;
Tang, Sung-Chun ;
Thundyil, John ;
Taylor, Stephen M. ;
Woodruff, Trent M. .
SHOCK, 2009, 32 (01) :4-16